| | ANZ 02P2 : IBIS-II |
| |
| | | An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS. |
| |
| | ANZ 0501 : LATER - Later adjuvant Aromatase inhibitor Therapy for postmenopausal women with Endocrine Responsive breast cancer |
| |
| | | Randomised trial of letrozole plus usual care versus usual care without letrozole to prevent new breast cancer events in postmenopausal women who have completed a minimum of 4 years of adjuvant endocrine therapy for early, hormone responsive breast cancer more than 1 year previous, and who are disease-free at trial entry. |
| |
| | ANZ 0702 / BIG 2-06 : ALTTO - Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study |
| |
| | | A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. |
| |
| | ANZ 0802 / CIRG / TRIO 012 : TRIO-012 |
| |
| | | A multicentre, multinational, randomised, double-blind, phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. |
| |
| | ANZ 0901 / PACCT - 1 : TAILORx - Trial Assigning IndividuaLized Options for Treatment |
| |
| | | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial |
| |
| | ANZ 1001 : SORBET - Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen |
| |
| | | A single arm phase II study of the efficacy of tamoxifen in triple negative (oestrogen receptor alpha negative, progesterone receptor negative, HER-2 negative) but oestrogen receptor beta positive metastatic breast cancer. |
| |
| | IBCSG 22-00 : Maintenance Chemotherapy |
| |
| | | Low dose cytotoxics as anti-angiogenesis treatment following adjuvant induction chemotherapy for patients with ER-Negative and PgR negative breast cancer. |
| |
| | IBCSG 25-02 / BIG 3-02 : TEXT - Tamoxifen and Exemestane Trial |
| |
| | | A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer. |
| |
| | IBCSG 34-05 / SWOG S0230 : POEMS - Prevention Of Early Menopause Study |
| |
| | | Phase III trial of LHRH analogue administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormonal receptor-negative breast cancer. |
| |
| | IBCSG 35-07 / BIG 1-07 : SOLE - Study Of Letrozole Extension |
| |
| | | A Phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years or prior adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, node-positive early stage breast cancer. |
| |